Among the key regulators of resistance to bevacizumab, phosphofructokinase-1 muscle isoform (PFKM), emerged with Eg5 is an essential partner to trigger this molecular phenomenon: cytosolic PFKM interacts with Eg5, which, in turn, promotes GBM invasion [61]. This evidence concerns the gene PFKM and glioblastoma.